{"database":"biostudies-literature","file_versions":[],"scores":null,"additional":{"submitter":["Deshmukh HA"],"funding":["Medical Research Council","National Institute for Health Research (NIHR)","European Commission FP7"],"pagination":["1000-1011"],"full_dataset_link":["https://www.ebi.ac.uk/biostudies/studies/S-EPMC3329377"],"repository":["biostudies-literature"],"omics_type":["Unknown"],"volume":["53(5)"],"pubmed_abstract":["We carried out a genome-wide association study (GWAS) of LDL-c response to statin using data from participants in the Collaborative Atorvastatin Diabetes Study (CARDS; n = 1,156), the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT; n = 895), and the observational phase of ASCOT (n = 651), all of whom were prescribed atorvastatin 10 mg. Following genome-wide imputation, we combined data from the three studies in a meta-analysis. We found associations of LDL-c response to atorvastatin that reached genome-wide significance at rs10455872 (P = 6.13 × 10(-9)) within the LPA gene and at two single nucleotide polymorphisms (SNP) within the APOE region (rs445925; P = 2.22 × 10(-16) and rs4420638; P = 1.01 × 10(-11)) that are proxies for the ε2 and ε4 variants, respectively, in APOE. The novel ass"],"journal":["Journal of lipid research"],"pubmed_title":["Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a)."],"pmcid":["PMC3329377"],"funding_grant_id":["FP7_223004","G9521010","NF-SI-0508-10116"],"pubmed_authors":["Ford I","Neil A","Hyde C","Poulter N","Stanton AV","Durrington PN","Hitman GA","Betteridge DJ","Jukema JW","Chatterjee A","Johnson T","DeMicco DA","Charlton-Menys V","Sever P","Caulfield M","Deshmukh HA","Fuller JH","Postmus I","Livingstone S","McKeigue PM","Shields DC","Colhoun HM","Calle RA","Trompet S"],"additional_accession":[]},"is_claimable":false,"name":"Genome-wide association study of genetic determinants of LDL-c response to atorvastatin therapy: importance of Lp(a).","description":"We carried out a genome-wide association study (GWAS) of LDL-c response to statin using data from participants in the Collaborative Atorvastatin Diabetes Study (CARDS; n = 1,156), the Anglo-Scandinavian Cardiac Outcomes Trial (ASCOT; n = 895), and the observational phase of ASCOT (n = 651), all of whom were prescribed atorvastatin 10 mg. Following genome-wide imputation, we combined data from the three studies in a meta-analysis. We found associations of LDL-c response to atorvastatin that reached genome-wide significance at rs10455872 (P = 6.13 × 10(-9)) within the LPA gene and at two single nucleotide polymorphisms (SNP) within the APOE region (rs445925; P = 2.22 × 10(-16) and rs4420638; P = 1.01 × 10(-11)) that are proxies for the ε2 and ε4 variants, respectively, in APOE. The novel ass","dates":{"release":"2012-01-01T00:00:00Z","publication":"2012 May","modification":"2025-04-18T14:46:39.403Z","creation":"2019-03-27T00:52:27Z"},"accession":"S-EPMC3329377","cross_references":{"pubmed":["22368281"],"doi":["10.1194/jlr.P021113"]}}